ONO Takahiro

写真a

Affiliation

Graduate School of Medicine  Doctorial Course in Medicine  Organ Function-Oriented Medicine  Department of Neurosurgery

Graduating School 【 display / non-display

  •  
    -
    2009.03

    Akita University   Faculty of Medicine   Graduated

Graduate School 【 display / non-display

  •  
    -
    2015.03

    Akita University  Graduate School, Division of Medicine  Doctor's Course  Completed

Studying abroad experiences 【 display / non-display

  • 2015.11
    -
    2017.06

    Germany   Guest Researcher, Department of Neuropathology, Institute of Pathology, University Heidelberg

Campus Career 【 display / non-display

  • 2017.07
    -
    Now

    Akita University   Graduate School of Medicine   Doctorial Course in Medicine   Organ Function-Oriented Medicine   Assistant Professor  

 

Research Career 【 display / non-display

  • Refinement of IDH-mutated glioma classification and grading

    International Joint Research Projects  

    Periods of research:

    2015.11
    -
    2017.10

    Classification of research form:International Collaboration

  • Diagnostic significance of amino acid tracers for evaluation of temozolomide therapy with interferon-beta and bevacizumab in temozolomide-resistant malignant glioma

    Grant-in-Aid for Scientific Research  

    Periods of research:

    2011.04
    -
    2015.03

    Classification of research form:Collaboration within Japan

Thesis for a degree 【 display / non-display

  • Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma

    Takahiro Ono, Toshio Sasajima, Yoshihiro Doi, Shuntaro Oka, Masahiro Ono, Masaru Kanagawa, Atsumi Baden, Kazuo Mizoi, Hiroaki Shimizu 

      2015.03

    Domestic Co-author

Published Papers 【 display / non-display

  • Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group

    Ono T, Sasajima T, Shimizu H, et al

    Neurologia medico-chirurgica ( 一般社団法人 日本脳神経外科学会 )    2020.11  [Refereed]

    Domestic Co-author

    <p>Pleomorphic xanthoastrocytoma (PXA) is a rare glial tumor, however, its histological differentiation from high-grade gliomas is often difficult. Molecular characteristics may contribute to a better diagnostic discrimination. Prognostic factors of PXA are also important but few relevant reports have been published. This study investigated the molecular features and prognostic factors of PXAs. Seven university hospitals participated in this study by providing retrospective clinical data and tumor samples of PXA cases between 1993 and 2014. Tumor samples were analyzed for immunohistochemical (IHC) neuronal and glial markers along with Ki67. The status of the BRAF and TERT promoter (TERTp) mutation was also evaluated using the same samples, followed by feature extraction of PXA and survival analyses. In all, 19 primary cases (17 PXA and 2 anaplastic PXA) were included. IHC examination revealed the stable staining of nestin and the close association of synaptophysin to NFP. Of the PXA cases, 57% had the BRAF mutation and only 7% had the TERTp mutation. On univariate analysis, age (≥60 years), preoperative Karnofsky performance status (KPS) (≤80%), and marked peritumoral edema were significantly associated with progression-free survival (PFS). No independent factor was indicated by the multivariate analysis. In conclusion, PXA was characterized by positive nestin staining and a few TERTp mutations. The neuronal differential marker and BRAF status may help in diagnosis. Patient age, preoperative KPS, and marked perifocal edema were associated with PFS. The present study is limited because of small number of cases and its retrospective nature. Further clinical study is needed.</p>

    DOI CiNii

  • Novel, improved grading system(s) for IDH‑mutant astrocytic gliomas

    Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A.

    Acta Neuropathologica     2018.07  [Refereed]

    International Co-author

  • Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report

    Ono T, Reinhardt A, Takahashi M, Nanjo H, Kamataki A, von Deimling A, Shimizu H

    Acta Neurochirurgica ( Acta Neurochirurgica )  162 ( 12 ) 3019 - 3024   2020.12  [Refereed]

    International Co-author

    DOI

  • Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma

    Stichel D, Ebrahimi A, Reuss DE, Schrimpf D, Ono T, Shirahata M, et al.

    Acta Neuropathologica ( Acta Neuropathologica )  136 ( 5 ) 793 - 803   2018.11  [Refereed]

    International Co-author

    DOI

  • Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma

    Ono T, Sasajima T, Doi Y, Oka S, Ono M, Kanagawa M, Baden A, Mizoi K, Shimizu H

    Nuclear medicine and biology     2015.07  [Refereed]

    Domestic Co-author

display all >>